Ceftazidime-avibactam
ApprovedSmall molecule
PfizerCeftazidime-avibactam is one of 114 small molecule programs targeting Nosocomial Infection. It is currently in Approved.
6
Indications
16
Total Trials
6
Active Trials
113
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Ceftazidime-avibactam
PfizerApproved
Primaxin
PfizerPreclinical
Prevacid
TakedaPreclinical
Innohep
Alnylam PharmaceuticalsPreclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Retrovir
BBp Consulting, Inc
Preclinical
Zantac 150
CChattem
Preclinical
Pepcid
KKenvue Brands
Preclinical
Mucinex
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Infections2 trials
Nosocomial Infection1 trial
Aztreonam1 trial
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03978091·48 enrolled
9 more indications
Intensive Care Unit1 trial
Critically Ill Patients1 trial
Urinary Tract Infection1 trial
Gram Negative Infections1 trial
Gram-Negative Bacterial Infections1 trial
Mortality1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ceftazidime-avibactam. EMBL-EBI & Wellcome Sanger Institute.
- [4]